Citations (12)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
In Sun Goak, Jin A Lee, Min Ho Jeong, Seol Ju Moon & Min Gul Kim. (2022) Pharmacokinetics of a Fixed-Dose Combination of Teneligliptin Hydrochloride Hydrate and Modified-Release Metformin Under Fasting and Fed Conditions in Healthy Subjects. Drug Design, Development and Therapy 16, pages 4439-4448.
Read now
Read now
Ping Zou, Mingxing Guo & Jingbo Hu. (2022) Evogliptin for the treatment option for type 2 diabetes: an update of the literature. Expert Review of Clinical Pharmacology 15:6, pages 747-757.
Read now
Read now
Hyounggyoon Yoo, Yun Kim, In-Jin Jang, Kyung-Sang Yu & SeungHwan Lee. (2020) Pharmacokinetic/Pharmacodynamic Interactions Between Evogliptin and Glimepiride in Healthy Male Subjects. Drug Design, Development and Therapy 14, pages 5179-5187.
Read now
Read now
Dae Young Lee, Ju-Hyun Kim, Hyun Joo Shim, Hyeon-Uk Jeong & Hye Suk Lee. (2018) Absorption, metabolism, and excretion of [14C]evogliptin tartrate in male rats and dogs. Journal of Toxicology and Environmental Health, Part A 81:11, pages 453-464.
Read now
Read now
Hong-Kyun Kim & Young-Seok Park. (2017) Plasma concentration of metformin and dexamethasone after administration through Osseogate. Drug Delivery 24:1, pages 437-442.
Read now
Read now
Articles from other publishers (7)
Byungwook Kim, Dha Woon Im, Heejae Won, Jung Sunwoo, Seung Seok Han, Hajeong Lee, Dong Ki Kim, Kook‐Hwan Oh, Kwon Wook Joo, Yon Su Kim, Joo‐Youn Cho, SeungHwan Lee, Jaeseong Oh, In‐Jin Jang & Yong Chul Kim. (2023) Effect of haemodialysis on the pharmacokinetics and pharmacodynamics of evogliptin. Diabetes, Obesity and Metabolism 25:6, pages 1769-1776.
Crossref
Crossref
Dong Han Won, Heejun Park, Eun-Sol Ha, Hwan-Ho Kim, Sun Woo Jang & Min-Soo Kim. (2021) Optimization of bilayer tablet manufacturing process for fixed dose combination of sustained release high-dose drug and immediate release low-dose drug based on quality by design (QbD). International Journal of Pharmaceutics 605, pages 120838.
Crossref
Crossref
Taegon Hong, Byung Hak Jin, Choon Ok Kim, Byung Won Yoo, Dasohm Kim, Jung Il Lee, Beom Kyung Kim, Sang Hoon Ahn, Do Young Kim, Jun Yong Park & Min Soo Park. (2020) Pharmacokinetics and safety of evogliptin in hepatically impaired patients. British Journal of Clinical Pharmacology 87:7, pages 2757-2766.
Crossref
Crossref
Deep Dutta, Saptarshi Bhattacharya, Aishwarya Krishnamurthy, LokeshKumar Sharma & Meha Sharma. (2020) Efficacy and safety of novel dipeptidyl-peptidase-4 inhibitor evogliptin in the management of type 2 diabetes mellitus: A meta-analysis. Indian Journal of Endocrinology and Metabolism 24:5, pages 434.
Crossref
Crossref
Alexey V. Zilov, Sulaf Ibrahim Abdelaziz, Afaf AlShammary, Ali Al Zahrani, Ashraf Amir, Samir Helmy Assaad Khalil, Kerstin Brand, Nabil Elkafrawy, Ahmed A.K. Hassoun, Adel Jahed, Nadim Jarrah, Sanaa Mrabeti & Imran Paruk. (2019) Mechanisms of action of metformin with special reference to cardiovascular protection. Diabetes/Metabolism Research and Reviews 35:7.
Crossref
Crossref
Poonam Giri, Shuchi Joshi & Nuggehally R Srinivas. (2018) Regression modeling strategy for prediction of AUC of evogliptin, a novel dipeptidyl peptidase IV inhibitor in humans, using single dose PK data. International Journal of Pharmacokinetics 3:1, pages 23-38.
Crossref
Crossref
Jaeseong Oh, Andrew HyoungJin Kim, SeungHwan Lee, Hyunjeong Cho, Yon Su Kim, Mi Young Bahng, Seo Hyun Yoon, Joo‐Youn Cho, In‐Jin Jang & Kyung‐Sang Yu. (2016)
Effects of renal impairment on the pharmacokinetics and pharmacodynamics of a novel dipeptidyl peptidase‐4 inhibitor, evogliptin (
DA
‐1229)
. Diabetes, Obesity and Metabolism 19:2, pages 294-298.
Crossref
Crossref